By Fineline Cube Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) announced that its two Category 1 chemical drugs, NH130 and NH302, have received Investigational New Drug (IND) approvals from China’s National Medical Products Administration (NMPA), clearing the path for clinical trials of both candidates.
IND Approval Summary
| Item | NH130 (citrate) | NH302 |
|---|---|---|
| Drug Category | Category 1 chemical drug | Category 1 chemical drug |
| Mechanism | 5‑HT2A receptor inverse agonist | Peripherally selective kappa opioid receptor agonist |
| Target Indications | Schizophrenia; Alzheimer’s disease psychosis (ADP) | Acute pain |
| Regulatory Status | IND approved by NMPA | IND approved by NMPA |
| Announcement Date | 18 Aug 2026 | 18 Aug 2026 |
Drug Profile – NH130 Citrate
- Mechanism: Potent 5‑HT2A receptor inverse agonist intended for schizophrenia and Alzheimer’s disease psychosis (ADP)
- Preclinical Efficacy: Demonstrated effectiveness in animal models of schizophrenia and ADP without impairing motor function
- Safety Profile: Minimal adverse effects such as cardiotoxicity and phospholipidosis
- Additional Advantages: Wide safety window and favorable pharmacokinetic properties
Drug Profile – NH302
- Mechanism: Peripherally selective kappa opioid receptor agonist intended for acute pain
- Preclinical Efficacy: Strong agonistic activity at kappa receptors with marked analgesic efficacy across multiple animal pain models
- Differentiators: Low effective dose, long duration of action, and a broad safety margin against sedation
- Positioning: Acute pain therapy with significant clinical advantages, with peripheral selectivity potentially limiting central opioid‑related liabilities
Market Impact & Outlook
- CNS Portfolio Expansion: The dual IND approvals reinforce Nhwa Pharmaceutical’s positioning in central nervous system drug development, spanning psychosis and pain — two areas of high unmet need in China’s aging society.
- Addressing Alzheimer’s Psychosis: ADP currently has limited approved treatment options globally; NH130’s motor‑function‑sparing profile and wide safety window could address a key limitation of existing antipsychotics in elderly patients.
- Non‑Sedating Pain Option: NH302’s peripheral kappa selectivity and broad safety margin against sedation position it as a potential alternative to centrally acting opioids for acute pain — a segment facing intense regulatory and safety scrutiny.
- Watch Items: First‑in‑human trial design and enrollment timelines for both assets, emerging safety/efficacy readouts, and potential partnering interest given the global demand for differentiated CNS assets.
Forward-Looking Statements
This brief contains forward‑looking statements regarding clinical development, regulatory outcomes, and commercial expectations for NH130 and NH302. Actual results may differ due to risks including early‑stage clinical uncertainty, regulatory decisions, and competitive dynamics.-Fineline Info & Tech